

AS269
Binding domain
Site specific conjugation of AS269
Light chain
Heavy chain
ARX788

FIG. 1



Waterfall Plot for ACE-BREAST-01 (1.5mg/kg)
Best Response
SD
PR
Change from baseline (%)
10%
0%
-10%
-20%
-30%
-40%
-50%
-60%
-70%
-80%
-90%
-100%
12.14%
-6.03%
-6.57%
-10.74%
-22.43%
-26.40%
-27.59%
-28.57%
-29.97%
-32.86%
-34.44%
-34.65%
-40.80%
-41.61%
-44.62%
-44.66%
-47.33%
-47.37%
-49.76%
-55.63%
-68.89%
-71.55%
-71.61%
-72.42%
-81.31%
-87.35%
-100.00%
-100.00%
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Patient Counter

FIG. 2



Spider Plot for ACE-BREAST-01 (1.5mg/kg)
20%
0%
-20%
-40%
-60%
-80%
-100%
Change from baseline (%)
0
200
400
600
Study Day
Best Response
PR
SD

FIG. 3



Swimmer Lane Plot for ACE-Breast-01
(1.5 mg/kg)
Best Response
PR
SD
Subject
Time on Therapy (days)
0
200
400
600
PR
EOT
Ongoing
SD

FIG. 4



Waterfall Plot for ACE-PAN TUMOR-01 (1.5 mg/kg Q4W)
Best Response
SD
PR
12.00%
-55.56%
-92.59%
10%
0%
-10%
-20%
-30%
-40%
-50%
-60%
-70%
-80%
-90%
Change from baseline (%)
1
2
3
Patient Counter

FIG. 5



Swimmer Lane Plot for ARX788-111
(1.5 mg/kg)
Dose Regimen
1.5 Q3W
Subject
Time on Therapy (days)
0
200
400
600
Marker Definitions
PR Confirmed
First PD
PR Not Confirmed
Continuing on Therapy
Dose Reduction

FIG. 6



Waterfall Plot for ARX788-111 (1.3 and 1.5mg/kg)
Dose Level
1.3 Q3W
1.3 Q4W
1.5 Q3W
Change from baseline (%)
10%
0%
-10%
-20%
-30%
-40%
-50%
-60%
-70%
-80%
-90%
-100%
Patient Counter
1
3
5
7
9
11
13
15
17
19
21
23
25
27
29
31
33
35
37
39
41
43
16.67%
15.40%
12.14%
6.14%
4.40%
2.91%
0.62%
-6.03%
-8.97%
-10.74%
-22.43%
-26.40%
-27.58%
-28.57%
-35.97%
-32.86%
-34.44%
-34.65%
-37.11%
-40.80%
-41.61%
-44.82%
-44.96%
-47.03%
-47.37%
-49.76%
-54.17%
-55.93%
-61.33%
-65.53%
-69.16%
-68.89%
-71.55%
-71.81%
-72.42%
-75.37%
-81.31%
-83.18%
-87.18%
-87.85%
-89.01%
-100.00%
-100.00%
-100.00%

FIG. 7





Swimmer Lane Plot for ARX788-111
(1.3 mg/kg)
Subject
01055 PR
01054 PR
01053 PR
01051 PR
01050 SD
01049 SD
01048 SD
01042 PR
01038 PR
01029 PD
01028 SD
01027 SD
01057 PR
01041 PR
01040 PD
01035 PR
0
200
400
600
800
Time on Therapy (days)
Dose Regimen
1.3 Q3W
1.3 Q4W
Marker Definitions
PR Confirmed
PR Not Confirmed
Dose Reduction
First PD
Continuing on Therapy

FIG. 8




Group	Median DOR (days)	95% CI
1.3 mg/kg Q3W/Q4W	392	(63, -)
1.5 mg/kg	438	(160, -)

FIG. 9




Group	Median DOR (days)	95% CI
1.3 mg/kg Q3W	NR	(194, -)
1.5 mg/kg Q3W	438	(160, -)

FIG. 10



Group	Median PFS (days)	95% CI
1.3 mg/kg Q3W/Q4W	231	(127, -)
1.5 mg/kg	317	(259, -)

FIG. 11



Group	Median PFS (days)	95% CI
1.3 mg/kg Q3W	231	(127, -)
1.5 mg/kg Q3W	317	(259, -)

FIG. 12



Prior to treatment
After 2 cycles of ARX788
After 4 cycles of ARX788

FIG. 13